Content
11/29/2023
Morrisville, NC USA
Arrivo BioVentures
completed $45.25 million Series B Round funding. Investors include
Orlando Health Ventures (lead), Celesta Capital, Rex Health Ventures, Solas Bioventures.
About
At Arrivo, we strive to set a new standard in drug development that starts with the selection of drug candidates and runs throughout clinical development. Our approach and decision-making has delivered a history of excellent returns and product successes that makes us the trusted partner for industry and investors.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
